Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Multivariate regression model assessing the associations between 6MWD and SSc characteristics

From: Factors associated with the 6-minute walk distance in patients with systemic sclerosis

  β (95% CI) p
Male (vs female) 58.9 (22.6; 95.2) 0.002
Age (per 1-year increment) –2.8 (–3.9; –1.7) <10–3
Disease duration since diagnosis (per 1-year increment) –0.7 (–2.5; 1.0) 0.42
BMI (per 1-kg/m2 increment) –2.7 (–5.1; –0.2) 0.03
Smoking history (vs no history) –8.2 (–33.9; 17.5) 0.53
History of venous thrombosis (vs no history) –10.8 (–48.6; 26.9) 0.57
History of arterial thrombosis (vs no history) –39.6 (–77.9; –1.4) 0.04
dcSSc (vs lcSSc) –22.7 (–57.6; 12.2) 0.20
PAH (vs no PAH) –79.2 (–129.7; –28.8) 0.002
ILD (vs no ILD)    0.15
 Limited ILD 22.0 (–6.9; 50.9)  
 Extensive ILD –14.7 (–55.8; 26.4)  
Joint symptoms (vs no symptoms) –16.5 (–41.6; 8.6) 0.20
Muscle symptoms (vs no symptoms) –7.5 (–40.6; 25.7) 0.66
Hemoglobin (per 1-g/dl increment) 9.2 (–0.8; 19.1) 0.07
CRP (per 1-mg/L increment) –4.3 (–6.7; –1.9) <10–3
Estimated GFR (per 1-ml/min/1.73 m2 increment) 0.2 (–0.4; 0.9) 0.46
Initial HR (per 1-bpm increment) –1.1 (–2.2; –0.1) 0.03
ΔHR (per 1-bpm increment) 2.8 (1.8; 3.8) <10–6
LVEF (per 1% increment) 1.2 (–0.5; 2.9) 0.15
Positive chronotropic drug intake (vs no intake) 14.2 (–44.3; 72.6) 0.63
Negative chronotropic drug intake (vs no intake) –25.3 (–52.3; 1.7) 0.07
  1. N = 192. R 2 = 0.59, adjusted R 2 = 0.54
  2. β coefficients expressed in meters
  3. 6MWD 6-minute walk distance, BMI body mass index, CI confidence interval, CRP C-reactive protein, dc diffuse cutaneous, GFR glomerular filtration rate, HR heart rate, ILD interstitial lung disease, lc limited cutaneous, LVEF left ventricle ejection fraction, PAH pulmonary arterial hypertension, SSc systemic sclerosis, Δ variation of